跳至主要内容
临床试验/NCT06837441
NCT06837441已完成不适用

Atrial Fibrillation Termination Versus Prespecified Ablation for Persistent Atrial Fibrillation:A Pilot Study

Shanghai Chest Hospital1 个研究点 分布在 1 个国家目标入组 195 人开始时间: 2023年1月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
195
试验地点
1
主要终点
Freedom from any documented atrial arrhythmia - atrial fibrillation (AF), atrial tachycardia (AT), or atrial flutter (AFL) - of more than 30 seconds, excluding the initial 3 months blanking period, at a minimum of 12 months follow up after a single ablat

研究概览

简要总结

The design of this study is an intervention, randomized, controlled study and contains two randomized groups:(1)AF-termination group;(2)Prespecified-ablation group.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • •aged between 18 and 80 years old;
  • •Patients undergoing a first-time ablation procedure for PersAF, and in spontaneous AF at the beginning of the procedure;
  • •Diagnosed as persistent AF according to the latest clinical guidelines,with atrial fibrillation lasting for at least one month;
  • •Ineffective or intolerable to ≥1 anti-arrhythmia drug treatment;
  • •Patients must be able and willing to provide written informed consent to participate in this study;
  • •Patients must be willing and able to comply with all study follow- up requirements.

排除标准

  • •.Uncontrolled congestive heart failure, EF <35%;
  • •. History of severe valve disease and/or prosthetic valve replacement;
  • •. Myocardial infarction or stroke within 6 months;
  • •. Severe congenital heart disease;
  • •. Left atrial diameter ≥60mm;
  • •. Contrast agent allergy;
  • •. The use of anticoagulant drugs is contraindicated;
  • •. Severe lung disease;
  • •. Left atrial thrombus confirmed by preoperative esophageal ultrasound;
  • •.Contraindications for cardiac catheterization;
  • •.Prior left atrial ablation (surgical or catheter);
  • •.Have performed any cardiac surgery within 2 months;
  • •.Poor general health;
  • •.Life expectancy < 12 months, including factors such as physical inability to tolerate ablation or unstable disease conditions.-

研究组 & 干预措施

AF-termination group

Experimental

干预措施: Atrial Fibrillation Termination (Procedure)

Prespecified-ablation group

Sham Comparator

干预措施: Prespecified Ablation (Procedure)

结局指标

主要结局

Freedom from any documented atrial arrhythmia - atrial fibrillation (AF), atrial tachycardia (AT), or atrial flutter (AFL) - of more than 30 seconds, excluding the initial 3 months blanking period, at a minimum of 12 months follow up after a single ablat

时间窗: 12 months

次要结局

  • Freedom from AF after a single procedure without anti-arrhythmic medications (excludes the blanking period) at 12 months;(12 months)
  • Freedom from AF/AT/AFL after a single procedure with/without anti-arrhythmic medications (excludes the blanking period) at 12 months(12 months)
  • Freedom from AF after a single procedure with/without anti-arrhythmic medications (excludes the blanking period) at 12 months(12 months)
  • Freedom from any AT episodes lasting more than 30 seconds after the blanking period without AADs after a single procedure(12 months)
  • Incidence of periprocedural adverse events.(12 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Xu Liu

Doctor Liu

Shanghai Chest Hospital

研究点 (1)

Loading locations...

相似试验

PerAF: AF Termination vs Prespecified Ablation | 临床试验